AVITA MEDICAL, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $18M | ↓-4.3% | — | — | — |
| 2025-09-30 | $17M | ↓-12.7% | $-13M | ↑+18.6% | -53.6% |
| 2025-06-30 | $18M | ↑+21.2% | $-10M | ↑+35.6% | -60.5% |
| 2025-03-31 | $19M | ↑+66.7% | $-14M | ↑+25.7% | -63.9% |
| 2024-12-31 | $18M | ↑+29.7% | — | — | — |
| 2024-09-30 | $20M | ↑+43.2% | $-16M | ↓-86.0% | -70.6% |
| 2024-06-30 | $15M | ↑+29.3% | $-15M | ↓-48.2% | -102.8% |
| 2024-03-31 | $11M | ↑+5.3% | $-19M | ↓-102.4% | -155.0% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 32 quarters
margin trajectory tells the operating-leverage storyGo deeper
RCEL Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyRCEL Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics